Posterior reversible encephalopathy syndrome associated with Guillain-Barré syndrome: Case report and clinical management considerations

J Clin Apher. 2020 Jun;35(3):231-233. doi: 10.1002/jca.21783. Epub 2020 Apr 14.

Abstract

Around half of the patients with Guillain-Barré syndrome (GBS) present autonomic dysfunction requiring admission to intensive care unit in up to a quarter of patients. Treatment of GBS consists of plasma exchange (PE) and intravenous immunoglobulins (IVIG). Posterior reversible encephalopathy syndrome (PRES) consists in a reversible subcortical vasogenic brain edema caused by endothelial damage triggered by abrupt blood pressure changes. We report on a woman who presented with PRES in the course of GBS treated first with IVIG, and then with PE. The present report underlines the challenge that the clinicians face when these two rare syndromes concur. The literature is not helpful considering that both blood pressure fluctuations and IVIG are reported to be involved in the pathogenesis of PRES. In the present letter, both pathogenic mechanisms and clinical management considerations are discussed.

Keywords: Guillain-Barré syndrome; dysautonomia; intravenous immunoglobulins; plasma exchange; posterior reversible encephalopathy syndrome.

Publication types

  • Case Reports

MeSH terms

  • Blood-Brain Barrier / diagnostic imaging
  • Brain / diagnostic imaging
  • Brain Edema / complications
  • Brain Edema / diagnostic imaging
  • Brain Edema / therapy
  • Endothelium, Vascular / immunology*
  • Fatal Outcome
  • Female
  • Guillain-Barre Syndrome / complications
  • Guillain-Barre Syndrome / diagnostic imaging
  • Guillain-Barre Syndrome / therapy*
  • Humans
  • Immunoglobulins, Intravenous / immunology*
  • Magnetic Resonance Imaging / methods
  • Middle Aged
  • Plasma Exchange / methods*
  • Posterior Leukoencephalopathy Syndrome / complications
  • Posterior Leukoencephalopathy Syndrome / diagnostic imaging
  • Posterior Leukoencephalopathy Syndrome / therapy*

Substances

  • Immunoglobulins, Intravenous